Show simple item record

dc.contributor.authorBhattacharya, IS
dc.contributor.authorHaviland, JS
dc.contributor.authorTurner, L
dc.contributor.authorStobart, H
dc.contributor.authorBalasopoulou, A
dc.contributor.authorStones, L
dc.contributor.authorKirby, AM
dc.contributor.authorKirwan, CC
dc.contributor.authorColes, CE
dc.contributor.authorBliss, JM
dc.contributor.authorPRIMETIME Trialists
dc.date.accessioned2021-08-10T14:18:46Z
dc.date.accessioned2022-03-23T15:29:54Z
dc.date.available2022-03-23T15:29:54Z
dc.date.issued2021-06-14
dc.identifier.citationTrials, 2021, 22 (1), pp. 397 - ?en_US
dc.identifier.issn1745-6215
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5048
dc.identifier.eissn1745-6215en_US
dc.identifier.eissn1745-6215
dc.identifier.doi10.1186/s13063-021-05345-yen_US
dc.identifier.doi10.1186/s13063-021-05345-y
dc.description.abstract<h4>Background</h4>For patients with early breast cancer considered at very-low risk of local relapse, risks of radiotherapy may outweigh the benefits. Decisions regarding treatment omission can lead to patient uncertainty (decisional conflict), which may be lessened with patient decision aids (PDA). PRIMETIME (ISRCTN 41579286) is a UK-led biomarker-directed study evaluating omission of adjuvant radiotherapy in breast cancer; an embedded Study Within A Trial (SWAT) investigated whether PDA reduces decisional conflict using a cluster stepped-wedge trial design.<h4>Methods</h4>PDA diagrams and a video explaining risks and benefits of radiotherapy were developed in close collaboration between patient advocates and PRIMETIME trialists. The SWAT used a cluster stepped-wedge trial design, where each cluster represented the radiotherapy centre and referring peripheral centres. All clusters began in the standard information group (patient information and diagrams) and were randomised to cross-over to the enhanced information group (standard information plus video) at 2, 4 or 6 months. Primary endpoint was the decisional conflict scale (0-100, higher scores indicating greater conflict) which was assessed on an individual participant level. Multilevel mixed effects models used a random effect for cluster and a fixed effect for each step to adjust for calendar time and clustering. Robust standard errors were also adjusted for the clustering effect.<h4>Results</h4>Five hundred twenty-one evaluable questionnaires were returned from 809 eligible patients (64%) in 24 clusters between April 2018 and October 2019. Mean decisional conflict scores in the standard group (N = 184) were 10.88 (SD 11.82) and 8.99 (SD 11.82) in the enhanced group (N = 337), with no statistically significant difference [mean difference - 1.78, 95%CI - 3.82-0.25, p = 0.09]. Compliance with patient information and diagrams was high in both groups although in the enhanced group only 121/337 (36%) reported watching the video.<h4>Conclusion</h4>The low levels of decisional conflict in PRIMETIME are reassuring and may reflect the high-quality information provision, such that not everyone required the video. This reinforces the importance of working with patients as partners in clinical trials especially in the development of patient-centred information and decision aids.en_US
dc.formatElectronicen_US
dc.format.extent397 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.relation.replaceshttps://repository.icr.ac.uk/handle/internal/4731
dc.relation.replacesinternal/4731
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.subjectPRIMETIME Trialistsen_US
dc.subjectHumansen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectChronic Diseaseen_US
dc.subjectDecision Makingen_US
dc.subjectDecision Support Techniquesen_US
dc.subjectResearch Designen_US
dc.subjectSurveys and Questionnairesen_US
dc.titleCan patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design.en_US
dc.typeJournal Article
dcterms.dateAccepted2021-05-29
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1186/s13063-021-05345-yen_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2021-06-14
dc.relation.isPartOfTrialsen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume22en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Trials & Statistics Unit
icr.researchteamBreast Cancer Radiotherapy
dc.contributor.icrauthorKirby, Annaen_US
dc.contributor.icrauthorBliss, Judithen_US
dc.contributor.icrauthorHaviland, Joanneen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0